Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
CellViderm
- Ownership
- Private
- Development stage
- Other
01
Overview
CellViderm is an emerging biotechnology company focused on developing advanced regenerative therapies for dermatological conditions and complex wound healing. The company utilizes its proprietary CellVi-Regen platform to engineer cell-based treatments and small molecule modulators that accelerate tissue repair and restore skin integrity. CellViderm's primary research efforts are directed toward chronic wounds, such as diabetic foot ulcers, and severe skin injuries. By integrating cell biology with innovative delivery systems, the company aims to provide transformative solutions for patients with limited treatment options in the wound care space.
- Therapeutic areas
- Dermatology
- Modalities
- Cell therapySmall molecule
- Industry
- Biotech
Beyond the preview
Go deeper on CellViderm.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CellViderm.